PARADIGM TEAMS UP WITH MEDICAL INSTITUTIONS IN MYANMAR TO ASSIST BREAST CANCER PATIENTS IN THE COUNTRY
Management of breast cancer and treatment options were the focus of a medical symposium organized under the aegis of the Myanmar Oncology Society in January of 2017. Attended by 70 leading oncologists, surgeons and general practitioners of the country, it was moderated by Prof. Soe Aung, President of Myanmar Oncology Society and Honorary Professor Medical Oncologist of Yangon General Hospital.
While the speakers presented studies on understanding the biology of tumors and various modalities for management of breast cancer, one thing that came through time and again in the discussions during and after the symposium is the plain lack of medication in the country, especially reliable quality cancer medicines.
“It is heart breaking to hear stories of patients, young women, who sold everything they had and still could not afford the medicine,” said Amal Naj, Chairman of Paradigm Pharma, which sponsored the symposium. “If we cannot help these patients then how can we justify our existence as a pharmaceutical business,” he said.
Paradigm has launched first of its cancer drugs in Myanmar that it is offering at deep discounts through select medical institutions under the company's Patient Access Program. The drugs are manufactured by Apotex Inc., a leading Canadian pharmaceutical company.